pyridinolcarbamate has been researched along with Cell Transformation, Neoplastic in 1 studies
Pyridinolcarbamate: A drug that has been given by mouth in the treatment of atherosclerosis and other vascular disorders, hyperlipidemias, and thrombo-embolic disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1408)
Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, Z | 1 |
| Peng, Y | 1 |
| Gao, J | 1 |
| Zhou, M | 1 |
| Shi, L | 1 |
| Zhao, F | 1 |
| Wang, C | 1 |
| Tian, X | 1 |
| Feng, L | 1 |
| Huo, X | 1 |
| Zhang, B | 1 |
| Liu, M | 1 |
| Fang, D | 1 |
| Ma, X | 1 |
1 other study available for pyridinolcarbamate and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
The p23 co-chaperone is a succinate-activated COX-2 transcription factor in lung adenocarcinoma tumorigenesis.
Topics: Adenocarcinoma of Lung; Carcinogenesis; Cell Transformation, Neoplastic; Cyclooxygenase 2; HSP90 Hea | 2023 |